Changde Medical Completes Over RMB 100 Million Series A+ Financing Led by Shanghai Biopharma Fund Under SRIC

Recently, Shanghai Changde Medical Technology Co., Ltd. (hereinafter referred to as “Changde Medical”^®”) Successfully completedA+ Round Financing Exceeding RMB 100 Million. This round of financing was led byLed by SHC, a fund under SIIC Capital, with co-investment from Industrial Capital Management Co., Ltd., and continued follow-on investment from existing shareholders Legend Capital and Huajie Gaojing.The funds will be primarily used for pre-market clinical trials and regulatory filings for the Company’s innovative products, international registration of its core products, and market expansion both domestically and overseas.

Changde Medical^®Founded in 2021, it is committed to providing comprehensive solutions for peripheral vascular diseases. Currently, Changde Medical^®A product portfolio has been established, covering interventional therapy for lower extremity arterial stenosis, thrombosis management, interventional therapy for venous diseases, and chronic disease management.

As of now, Changde Medical^®Seven medical device registration certificates have been obtained; three products have completed enrollment in pre-market clinical trials and entered the stage of submitting for regulatory approval, while multiple products have initiated CE certification applications. In addition, the company’s independently developed EF-Lumber^®Peripheral drug-eluting stents are currently in the clinical enrollment phase and were approved by the National Medical Products Administration (NMPA) in March 2025 to enter the Special Review Procedure for Innovative Medical Devices (“Green Channel”). Since December 2023, the first product, EF-Rhine^®Since the approval and market launch of the peripheral vascular constrained balloon dilation catheter, the company has rapidly expanded its commercialization efforts.

Changde Medical^®Miao Zhenghua, Chairman and General Managerstated: “We extend our gratitude to SHC, Industrial Capital Management Co., Ltd., and existing shareholders for their support of Changde Medical”^®trust and support. This round of financing will inject strong momentum into the company, accelerating the market access and commercialization of our core products in the domestic market, while also speeding up our expansion into overseas markets. We have always maintained strict control over product quality. While enhancing product accessibility, we accurately grasp changes in clinical needs. Through the coordinated development of both domestic and international markets, and a dual-drive strategy of independent R&D and strategic cooperation, we will continue to improve the efficiency of our commercial operations, driving the company to achieve steady and long-term growth on the path of high-quality development.”

Liang Weibin, Partner at SHCSHC stated: “The Shanghai Healthcare Capital (SHC) continues to closely monitor the innovative medical device sector. The penetration rate of peripheral vascular interventional procedures remains relatively low, indicating that the peripheral medical device market features significant unmet clinical needs and high growth potential. Against the backdrop of domestic substitution and the global expansion of Chinese innovations, companies with strong product capabilities and advantageous product portfolios are well-positioned to seize first-mover advantages and rapidly gain market share. Changde Medical is committed to providing comprehensive peripheral solutions and stands out as a rare player in the peripheral intervention field that combines innovative products with efficient execution. Since its establishment, the company has rapidly advanced multiple products into clinical trials and commercial launch, and it is expected to continue demonstrating its strong commercialization capabilities. We believe that Mr. Miao and his team have the ability to build Changde Medical into a core force in China’s innovative medical device industry, delivering a portfolio of products with superior performance and greater accessibility to a broad patient population.”